Skip to main content
Vivoryon Therapeutics N.V. logo

Vivoryon Therapeutics N.V. — Investor Relations & Filings

Ticker · VVY ISIN · NL00150002Q7 LEI · 3912004AMB0KGZXZYJ15 AS Manufacturing
Open in API
Filings indexed 400 across all filing types
Latest filing 2023-04-19 Earnings Release
Country NL Netherlands
Listing AS VVY

About Vivoryon Therapeutics N.V.

https://www.vivoryon.com/

Vivoryon Therapeutics N.V. is a clinical-stage precision medicine company focused on developing first-in-class therapies by targeting post-translational modifications of proteins. The company's scientific approach centers on inhibiting glutaminyl cyclases (QPCT and QPCTL), enzymes that catalyze pyroglutamate formation, a process implicated in the progression of various diseases. Its lead product candidate, varoglutamstat, is an orally administered small molecule QPCT/L inhibitor. Vivoryon is advancing its therapeutic pipeline for patients with inflammatory, fibrotic, and neurodegenerative diseases, with a strategic focus on conditions such as chronic kidney disease.

Recent filings

Filing Released Lang Actions
Vivoryon Therapeutics N.V. Reports Full Year 2022 Financial Results and Highlights Operational Progress
Earnings Release Classification · 98% confidence The document is titled "Vivoryon Therapeutics N.V. Reports Full Year 2022 Financial Results and Highlights Operational Progress" and explicitly details financial results for the twelve-month period ended December 31, 2022. It includes a detailed 'Statement of Operations and Comprehensive Loss' table comparing 2022 and 2021, and discusses R&D expenses, G&A expenses, and net loss. This content structure is characteristic of an Earnings Release (ER), which provides the initial announcement of periodical financial results, often accompanied by operational highlights. Although it contains detailed financial data, it is presented as a press release announcing the results, rather than the comprehensive, audited 10-K filing itself. The document also mentions a conference call to discuss these results, further supporting the ER classification. FY 2022
2023-04-19 English
Vivoryon Therapeutics N.V. to Report Full Year 2022 Financial Results and Operational Progress on April 19, 2023
Report Publication Announcement Classification · 98% confidence The document is a press release dated April 14, 2023, announcing that Vivoryon Therapeutics N.V. will publish its 'Full Year 2022 Financial Results and Operational Progress' on April 19, 2023. It provides details for a conference call and webcast related to this upcoming publication. Crucially, the document itself is not the full financial report (10-K or IR) but rather an announcement *about* the release of those results. According to Rule 2, when a document announces the publication of a report and provides details for an associated event (like a conference call), it fits the definition of a Report Publication Announcement (RPA). It is not the full financial report itself.
2023-04-14 English
Vivoryon Therapeutics N.V. Provides Progress Update on Varoglutamstat Clinical Development for the Treatment of Alzheimer's Disease
Regulatory Filings Classification · 95% confidence The document is a press release dated March 28, 2023, providing a 'Progress Update on Varoglutamstat Clinical Development for the Treatment of Alzheimer's Disease.' It details progress, safety data, and future timelines for two clinical studies (VIVIAD and VIVA-MIND). This content structure—a company announcement summarizing recent developments, data presentations (AD/PD conference), and future milestones—is characteristic of an Earnings Release (ER) or a general corporate update. Since it is not a full financial report (10-K or IR), nor a transcript (CT), nor a formal proxy/governance document, and it focuses on clinical progress which often accompanies financial reporting periods, the most fitting category is 'Earnings Release' (ER), as these updates frequently accompany quarterly results announcements, even if the primary focus here is clinical data. It is a high-level summary of operational/clinical progress, not the detailed financial report itself.
2023-03-28 English
Vivoryon Therapeutics N.V. to Present at Upcoming Conferences
Report Publication Announcement Classification · 99% confidence The document is a press release announcing that the CEO of Vivoryon Therapeutics N.V. will be presenting at several upcoming investor conferences (BioCapital Europe, Barclays Global Healthcare Conference, German Biotechnology Days). This type of announcement, which details future investor engagement events, does not fit neatly into the specific financial reporting categories (like 10-K, ER, IR) or corporate action categories (like DIV, CAP, SHA). It is a general corporate update aimed at investors regarding outreach activities. Since it is not a specific report, but rather an announcement about future events, and it doesn't fit the definitions for MANG, DIRS, or LTR, the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general category for miscellaneous regulatory or corporate announcements that don't fit elsewhere.
2023-02-21 English
Vivoryon Therapeutics N.V. to Present at the 2023 BIO CEO & Investor Conference
Investor Presentation Classification · 99% confidence The document is a press release announcing that Vivoryon Therapeutics N.V. will be presenting at the 2023 BIO CEO & Investor Conference. It details the date, time, and venue of the presentation and provides a brief overview of the company and its lead product. This type of announcement, which informs investors about participation in a specific industry or investor event, is best classified as an Investor Presentation (IP) announcement or, more broadly, a general regulatory/investor relations communication. Since the document itself is an announcement *about* a presentation, and not the presentation slides or a transcript, it fits best under the category for investor-focused communications. Given the options, 'Investor Presentation (IP)' is the most relevant category for an announcement regarding participation in a major investor conference where presentations are given, even though the actual presentation material is not attached. If the document were the actual presentation slides, IP would be certain. As a press release announcing participation, it is closely related to investor outreach. However, looking closely at the definitions, there isn't a specific code for 'Conference Presentation Announcement'. The content is highly focused on informing investors about an upcoming event where company strategy and financials will be discussed. It is not an Earnings Release (ER), a Capital Update (CAP), or a general Regulatory Filing (RNS). Given the context of informing investors about a presentation opportunity, IP is the closest fit for the *subject matter* being promoted, although RPA (Report Publication Announcement) is often used for announcements of reports. Since this is an announcement about an *event* rather than a *report*, and it is clearly aimed at investors, IP is chosen as the most contextually appropriate classification for this type of investor relations news.
2023-02-03 English
Vivoryon Therapeutics to Present a Clinical Update on its Novel Oral Small Molecule Varoglutamstat at Clinical Trials on Alzheimer's Disease Conference (CTAD)
Regulatory Filings Classification · 95% confidence The document is an announcement by Vivoryon Therapeutics stating that new data on their drug varoglutamstat will be presented at the 'Clinical Trials on Alzheimer's Disease conference (CTAD)'. It details the poster presentation information (number, theme, title, authors, date/time/location) and mentions where the poster will be made public. This is a press release announcing participation in a scientific conference and the presentation of clinical data, not the full financial report (10-K, IR), a formal earnings release (ER), or a transcript of a call (CT). Since it is an announcement about clinical trial data presentation, it fits best under the general 'Regulatory Filings' (RNS) category as a specific corporate update that doesn't match the other specialized codes like ER, CT, or IP. Given the short length and the nature of announcing external event participation, RNS is the most appropriate fallback.
2022-11-28 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.